NASCIMBENI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.150
EU - Europa 3.004
AS - Asia 1.832
SA - Sud America 301
AF - Africa 32
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.333
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.111
GB - Regno Unito 939
IT - Italia 744
SG - Singapore 562
HK - Hong Kong 531
CN - Cina 425
SE - Svezia 328
DE - Germania 297
BR - Brasile 261
RU - Federazione Russa 162
UA - Ucraina 94
FI - Finlandia 93
FR - Francia 81
TR - Turchia 75
BG - Bulgaria 67
VN - Vietnam 49
ID - Indonesia 41
IN - India 40
NL - Olanda 34
KR - Corea 27
LT - Lituania 26
BE - Belgio 22
CA - Canada 21
RO - Romania 20
IE - Irlanda 16
CH - Svizzera 14
AR - Argentina 12
AT - Austria 12
CZ - Repubblica Ceca 12
ES - Italia 11
BD - Bangladesh 10
VE - Venezuela 10
ZA - Sudafrica 9
AU - Australia 8
JP - Giappone 8
MX - Messico 8
MY - Malesia 7
UZ - Uzbekistan 7
EG - Egitto 6
MK - Macedonia 6
PH - Filippine 6
PK - Pakistan 6
EC - Ecuador 5
IR - Iran 5
PE - Perù 5
PL - Polonia 5
AZ - Azerbaigian 4
IQ - Iraq 4
KE - Kenya 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
DZ - Algeria 3
EE - Estonia 3
GR - Grecia 3
JM - Giamaica 3
SI - Slovenia 3
TW - Taiwan 3
BZ - Belize 2
EU - Europa 2
GE - Georgia 2
HR - Croazia 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
PY - Paraguay 2
RS - Serbia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CU - Cuba 1
DK - Danimarca 1
ET - Etiopia 1
GH - Ghana 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.333
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Santa Clara 804
Southend 620
Woodbridge 557
Ashburn 528
Hong Kong 528
Chandler 470
Seattle 447
Houston 435
Wilmington 397
Singapore 355
Cambridge 348
Ann Arbor 317
Nyköping 268
Dearborn 236
London 197
Jacksonville 117
Modena 113
Hefei 95
Beijing 83
San Diego 81
New York 75
Princeton 65
Sofia 65
Eugene 62
Helsinki 61
Izmir 53
Munich 53
Moscow 45
Rome 45
Milan 43
Jakarta 40
Council Bluffs 38
Shanghai 36
Bremen 25
Redwood City 24
Seoul 24
Fremont 22
Brussels 20
Nuremberg 19
Columbus 18
Bologna 17
San Mateo 17
Dong Ket 16
Padova 16
Reggio Emilia 16
Falls Church 15
São Paulo 15
Timisoara 15
Chicago 14
Los Angeles 14
Norwalk 14
The Dalles 14
Dublin 13
Hanoi 13
Boardman 12
Naples 12
Palermo 12
Parma 12
Frankfurt am Main 11
Nanjing 11
Turku 11
Toronto 10
Abbiategrasso 9
Dallas 9
Ho Chi Minh City 9
Turin 9
Cagliari 8
Fuzhou 8
Kilburn 8
Kunming 8
Paris 8
Augusta 7
Bari 7
Brno 7
Düsseldorf 7
Jinan 7
Verona 7
Des Moines 6
Falkenstein 6
Grafing 6
Johannesburg 6
Messina 6
Rio de Janeiro 6
Tashkent 6
Belo Horizonte 5
Brescia 5
Chiswick 5
Curitiba 5
Guangzhou 5
Hounslow 5
Lauterbourg 5
Nanchang 5
Perugia 5
Phoenix 5
San Jose 5
Wuhan 5
Baku 4
Bobbio 4
Boston 4
Totale 9.463
Salva come PNG Salva come JPEG
Nome #
Terapia antialadosteronica e prevenzione della cardiomiopatia cirrotica 571
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 432
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 263
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis 263
Drugs and acute porphyrias: reasons for a hazardous relationship 252
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk 243
ANTIALDOSTERONE THERAPY IN LIVER CIRRHOSIS: A ROLE FOR PREVENTION OF CIRROTHIC CARDIOMIOPATHY? 237
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 227
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV 224
Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? 222
Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes 218
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 212
Nonalcoholic fatty liver disease: Evolving paradigms 212
A critical appraisal of the use of ultrasound in hepatic steatosis 209
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis 208
Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? 208
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease 206
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 204
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 204
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 202
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy 199
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 197
Hypothyroidism and nonalcoholic fatty liver disease - A chance association? 192
Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy 191
From NAFLD in clinical practice to answers from guidelines. 191
MTHFR C677T polymorhism and hyperhomocysteinemia in patients with liver cirrhosis complicated by portal vein thrombosis and hepatocellular carcinoma 190
Alcohol and Steatosis: The Japanese Paradox 187
Role of Multidrug-Resistance Protein 2 in coproporphyrin transport: results from experimental studies in bile fistula rat models 184
Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: The “Musketeer” in the spotlight 182
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease 181
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? 180
Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? 178
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 177
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases 176
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 171
Insulin resistance in advanced liver cirrhosis : the role of liver dysfunction and the “dissociated” effect on glucose versus lipid and amino acid metabolism 169
Clinical relevance of liver histopathology and different histological classifications of NASH in adults 167
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 166
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans 160
Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk? 155
Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity? 152
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease 152
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? 151
Association between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis 151
Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? 146
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 146
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk 143
Hyperferritinemia and diagnosis of type 1 Gaucher disease 142
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease 141
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications 140
Sex Differences in NAFLD: State of the Art and Identification of Research Gaps 137
Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements 137
The genetic basis of Insulin resistance. A brief review 134
Global multi-stakeholder endorsement of the MAFLD definition 133
Non-alcoholic fatty liver disease: Diagnosis and investigation 133
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? 133
Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomeres involvement on line pubblication 03-Oct-2012Hepatology- 127
Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation? 121
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment 115
Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases 111
Hepatic and extrahepatic malignancies in NAFLD 111
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist 110
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? 110
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 98
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study 73
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group 70
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia 68
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 65
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry 63
Frailty after Liver Transplantation: A Complex Unexplored Issue 60
Colon cancer in a 12-year-old girl with hypertriglyceridemia 59
Metabolic Disorders in Liver Transplant Recipients: The State of the Art 34
Liver transplantation and nonalcoholic steatohepatitis: the state of the art 31
Splenomegaly: Dare to think rare 28
Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease 26
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease 25
Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease 20
Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN) 20
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease 20
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 18
Identifying possible homozygous familial hypercholesterolemia patients: An Italian experts' opinion 10
Diagnosi e storia naturale della steatosi epatica non alcolica. Performance e limiti delle tecniche diagnostiche invasive e non invasive e risultati del follow-up a lungo termine delle cirrosi criptogenetiche. 1
Totale 12.475
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.251
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.251
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.961 176 80 166 161 215 162 238 202 120 182 164 95
2021/20221.340 102 118 65 77 83 112 45 53 163 149 247 126
2022/20231.407 133 173 140 123 150 176 27 149 175 17 66 78
2023/2024829 34 53 79 69 162 75 56 82 22 23 56 118
2024/20253.350 82 46 99 191 613 447 319 215 342 201 357 438
2025/2026101 101 0 0 0 0 0 0 0 0 0 0 0
Totale 12.475